Provention Bio P/E 2025

Provention Bio Aktienanalyse

What does Provention Bio do?

Provention Bio Inc is a US biotechnology company specializing in the development of preventive therapies for autoimmune diseases and other chronic conditions. The company was founded in 2016 by a group of experienced biotech managers and has its headquarters in Oldwick, New Jersey. The history of Provention Bio begins with the recognition that many current treatments for autoimmune diseases such as type 1 diabetes, celiac disease, and lupus only aim to treat the symptoms of the disease rather than addressing their causes. Therefore, the company is committed to developing innovative and preventive therapies that directly target the causes of autoimmune diseases. Provention Bio's business model is based on sourcing and developing new therapies through to commercialization. The company is dedicated to early-stage research and development and works closely with academic institutions, government agencies, and other companies to achieve its goals. Additionally, Provention Bio invests in clinical trials to prove the efficacy of its therapies and ensure their approval by regulatory authorities. The various divisions of Provention Bio encompass some of the most important autoimmune diseases currently lacking effective cures. These include type 1 diabetes, celiac disease, lupus, MS, and other rare autoinflammatory diseases. Provention Bio's products aim to regulate the immune system and enhance the body's self-healing by influencing biological processes. One of Provention Bio's key products is Teplizumab, a preventive medication for the treatment of type 1 diabetes. The company has acquired the exclusive global rights to this medication, relying on promising results from its clinical trials. Since its FDA approval in 2021, the medication has filled an important market need. Additionally, Provention Bio has several other potential therapies in its pipeline. Among them is PRV-3279, a medication specifically developed for the treatment of celiac disease, currently in phase 2 clinical trials. Additionally, Teplizumab is being investigated for use in other autoimmune diseases such as lupus and MS. The goal of Provention Bio is to positively impact the quality of life and health of millions of people worldwide. The company is working hard to develop innovative preventive therapy approaches that focus on the causes of autoimmune diseases rather than just treating the symptoms. In doing so, Provention Bio is a significant addition to the wide range of existing treatment options by significantly expanding therapeutic choices. In summary, Provention Bio Inc is considered an emerging biotechnology company with great potential in the preventive treatment of autoimmune diseases. The company has a promising pipeline of therapies that have the potential to improve the lives of millions of people worldwide. The company aims to develop preventive and effective therapies that directly address the causes of autoimmune diseases. Provention Bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Provention Bio's P/E Ratio

The Price to Earnings (P/E) Ratio of Provention Bio is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Provention Bio's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Provention Bio is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Provention Bio’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Provention Bio stock

What is the price-to-earnings ratio of Provention Bio?

The price-earnings ratio of Provention Bio is currently -16.44.

How has the price-earnings ratio of Provention Bio changed compared to last year?

The price-to-earnings ratio of Provention Bio has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Provention Bio high compared to other companies?

Yes, the price-to-earnings ratio of Provention Bio is high compared to other companies.

How does an increase in the price-earnings ratio of Provention Bio affect the company?

An increase in the price-earnings ratio of Provention Bio would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Provention Bio affect the company?

A decrease in the price-earnings ratio of Provention Bio would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Provention Bio?

Some factors that influence the price-earnings ratio of Provention Bio are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Provention Bio pay?

Over the past 12 months, Provention Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Provention Bio is expected to pay a dividend of 0 USD.

What is the dividend yield of Provention Bio?

The current dividend yield of Provention Bio is .

When does Provention Bio pay dividends?

Provention Bio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Provention Bio?

Provention Bio paid dividends every year for the past 0 years.

What is the dividend of Provention Bio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Provention Bio located?

Provention Bio is assigned to the 'Health' sector.

Wann musste ich die Aktien von Provention Bio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Provention Bio from 10/8/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/8/2025.

When did Provention Bio pay the last dividend?

The last dividend was paid out on 10/8/2025.

What was the dividend of Provention Bio in the year 2024?

In the year 2024, Provention Bio distributed 0 USD as dividends.

In which currency does Provention Bio pay out the dividend?

The dividends of Provention Bio are distributed in USD.